Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE)
Key facts
- Who runs it
- Beth Israel Deaconess Medical Center
- Where
- Boston, United StatesSee the siteAlso in 1 other country, 2 sites
- Trial code
- Status
- Completed
- People taking part
- 160 people enrolled
- Started
- 25 Feb 2024
- Ended
- 18 Nov 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- EyeControl-Pro
- Control
- Record updated
- 3 December 2025
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Mechanically ventilated patients aged >=50 years
- RASS score of -3 to +1 and
- Anticipated to require >=24 hours of mechanical ventilation
Who cannot take part
- Receiving paralytic neuromuscular blocking agent (NMBA) infusion or anticipated need for NMBA use
- Have advanced dementia or cognitive impairment including post-concussive syndrome
- Have severe uncorrected psychiatric disorders
- Have uncorrected hearing or visual impairment
- Acute or subacute neurological disorder hindering communication or ability to participate in CAM ICU assessments
- Not expected to survive >=24 hours
- Have limitations in care (Do Not Resuscitate, or comfort-focused care orders)
- Enrolled in a clinical trial which prohibits co-enrollment
- Incarcerated
- Have no identified legally appointed representative (LAR)
- Are unable to communicate in the predominant local language (English at US site and English/Hebrew/Arabic/Russian in Israel)
- Refusal of treating clinical team
Where in United States
Also in 1 other country, 2 sites
- Beth Israel Deaconess Medical CenterBoston, United States
About the trial
What the trial wants to find out
The purpose of this research is to investigate whether addition of the EyeControl-Pro platform as an adjunct to standard guideline-based intensive care unit management of critically ill patients is effective in reducing delirium incidence and severity.
The 2 groups in the trial
- EyeControl-Pro assisted active intervention armExisting treatment, for comparison
Participants will wear the EyeControl-Pro device daily from 08:00-18:00 (extendable to 20:00; minimum 4 hours for compliance). On Day 1, onboarding includes a ≤2 min auditory tutorial, repeated daily for orientation. The device delivers up to 5 personalized family messages and 5 automated re-orientation messages per day, alternating approximately every 2 hours to maintain engagement and awareness. Slow-tempo music or white/brown noise plays in 15-minute sessions every 4 hours, modulated according to the patient's preferences and responses. The device performs twice-daily automated CAM-ICU assessments, scheduled within 45 minutes of blinded assessor CAM-ICU to allow comparison. Study team delirium assessments occur twice daily through Day 7, then once daily if in ICU for days 8-14, with MoCA/t-MoCA and HADS at Day 30 (+14 day window). Device use ends after 7 days, earlier if extubated, discharged, transitioned to comfort care, or in the event of death.
Treatment: EyeControl-Pro
- Sham ControlSham treatment, for comparison
Participants will wear an identical-appearing EyeControl device daily from 08:00-18:00 (extendable to 20:00; minimum 4 hours for compliance). On Day 1, onboarding includes a ≤2 min auditory tutorial introducing the device. No automated re-orientation messages, family messages, or music sessions are delivered. The device tracks eye state and logs activity but does not provide auditory feedback beyond the initial tutorial. Blinded study team members perform twice-daily CAM-ICU and CAM-ICU-7 assessments through Day 7, then once daily if in ICU for days 8-14. MoCA/t-MoCA and HADS assessments occur at Day 30 (+14 day window). Device is removed after 7 days, upon extubation, ICU discharge, comfort care transition, or death.
Treatment: Control
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE) : A Multicenter Randomized Controlled Trial
- Record updated
- 3 December 2025